Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory acute myeloid leukaemia
The oral IDH1 inhibitor ivosidenib put about a third of patients with relapsed or refractory IDH1-mutated acute myeloid leukaemia into remission, with some clearing the mutation altogether, leading to its approval.
Overview
Phase 1 dose-escalation and expansion study of 258 patients with IDH1-mutated advanced haematological cancers, including 179 with relapsed or refractory AML treated at 500 mg daily.
In the primary efficacy population the rate of complete remission or complete remission with partial haematological recovery was 30.4 percent, median duration of response 8.2 months, and 21 percent of responders had no detectable IDH1 mutation. Differentiation syndrome occurred in about one in ten.
- Complete remission or complete remission with partial haematological recovery in 30.4 percent; overall response 41.6 percent.
- Median overall survival 8.8 months in relapsed or refractory AML.
IDH1 testing at diagnosis and relapse now directs patients to a targeted oral drug; ivosidenib went on to be combined with azacitidine in newly diagnosed disease (AGILE).
- Single-arm study; responses were partial for most and relapse common.
- Differentiation syndrome and QT prolongation need monitoring.
Similar pages
not linked directly; found by shared links- TrialAGILE
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Ivosidenib.
- Key paperAGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Ivosidenib, New England Journal of Medicine.
- TermDifferentiation syndrome
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Ivosidenib.